Fig. 5

CCR2RA delivered intra-articularly at different time points after DMM surgery. a Four and b 7 weeks after DMM surgery, CCR2RA (BMS CCR2 22, R&D systems: 0.5 mg/kg, i.a.) or vehicle control (50% EtOH, i.a.) was intra-articularly administered and knee hyperalgesia was measured before injection, and 1, 2, and 4 h after injection. (n = 4 vehicle, n = 4 CCR2RA at DMM + 4 weeks) (n = 6 vehicle, n = 6 CCR2RA at DMM + 7 weeks) *p < 0.05, **p < 0.01 vs vehicle. Repeated measures two-way ANOVA with Bonferroni’s multiple comparisons test to compare CCR2RA to vehicle at each time point. Mean ± SEM